Testing for SARS-CoV-2 (Lab Diagnosis of COVID-19)

Updated July 15, 2021

What's New/Updated: Added information and a link to CDC's COVID-19 Viral Testing Tool.

Diagnostic Testing for SARS-CoV-2 in Persons with Symptoms and Suspected of COVID-19

Authorized assays for viral testing include those that detect SARS-CoV-2 nucleic acid or antigen. Viral (nucleic acid or antigen) tests check samples from the respiratory system (such as nasal or oral swabs or saliva) to determine whether an infection with SARS-CoV-2, the virus that causes COVID-19, is present.1 Viral tests are recommended to diagnose acute infection of both symptomatic and asymptomatic individuals, to guide contact tracing, treatment options, and isolation requirements.

Some tests are point-of-care tests, meaning results may be available at the testing site in less than an hour. Other tests must be sent to a laboratory, a process that may take at least 1-3 days.

- Molecular, RNA nucleic acid amplification test (NAAT) is the gold standard and should be used for identification and confirmation of infection in symptomatic persons suspected of COVID-19.

For initial diagnostic testing for SARS-CoV-2, the virus that causes COVID-19 the FDA has identified the following as appropriate types of specimens. Important: follow the instructions for use for the specific test method being used that has an approved FDA EUA.

- Nasopharyngeal (NP) specimen collected by a healthcare professional (HCP)
- Oropharyngeal (OP) specimen collected by an HCP using a swab;
- Mid-turbinate specimen collected by an HCP or by onsite self-collection using a specialized, flocked tapered swab; or
- Anterior nares specimen collected by an HCP or by onsite self-collection using a flocked swab, round foam swab, or spun fiber swab. For anterior nares specimen collection, a swab with a full-sized tip (OP-type swab) is generally preferred over a swab with a mini-tip (NP-type swab).
- Other types of specimens, e.g. saliva, based on FDA EUA instructions

Figure 1. Illustration of locations for collecting specimens for testing

- Personnel should adhere to standard procedures associated with other respiratory pathogens, such as seasonal influenza and other human coronaviruses, when they transport
specimens within a facility. Refer to CDC recommendations for more details on biosafety practices for specimens.

**Interpretation and Use of Cycle Threshold (Ct) Values**

Many but not all molecular test methods that use polymerase chain reaction (PCR) to amplify viral RNA also include a cycle threshold (Ct) value. The result the provider will see from an ordered test will be whether viral RNA is detected or not (qualitative). Occasionally a provider may be interested in the Ct value. Generally, the more template (e.g., SARS-CoV-2) that is in the original sample, the fewer the cycles that are needed before the target is detected and crosses this threshold. A lower value suggests there is a higher viral load (quantitative). The Frequently Asked Questions (FAQs) for PCR Testing Cycle Threshold (Ct) Value Interpretation document will have FAQs about Ct values.

- A lower Ct value suggests a higher viral load more often seen in those with acute infection. The Ct value also can be helpful in determining if someone who had initial infection develops new onset of symptoms weeks to months later. If tested again and the Ct is high, it may just be residual viral RNA and the symptoms may be from another cause. [see also Flu/COVID19 Testing Algorithm]
  - **Note:** The precise threshold between low (e.g., <33) or high (> 33) Ct value varies by brand of molecular test. The Clinical lab can provide this level of detail based on what test method is in use. In addition, a high Ct can be seen if the person is tested very early during acute infection.
- Ct values are not standardized across specimen sources, testing platforms, or laboratories. Therefore, they are not be routinely included in results of molecular tests that detect SARS-CoV-2.
- If a provider is interested in the Ct value for a test they ordered, they should consult their ministry’s infectious disease specialist to assist with interpretation and application to the specific case. If an infectious disease specialist is not available and the result may impact a time sensitive need, the ordering provider should contact the Clinical Director of the performing lab and request the Ct value.

**SARS-CoV-2 Testing**

- Anyone with symptoms of COVID-19, regardless of vaccination status, should receive a viral test as soon as possible.
- Asymptomatic Health Care Professionals, regardless of vaccination status who have had a high-risk exposure should have a series of two viral tests for SARS-CoV-2 infection. In these situations, testing is recommended as soon as possible after the date of exposure and 5–7 days after exposure. See the Colleague Exposure Assessment Tool for more details.
  - The initial test following notification from the HCP of a high-risk exposure is not needed if the notice is received > 48 hours after the high-risk exposure incident. The rationale is the test between 5-7 days after the exposure incident would most likely identify if the exposure resulted in transmission to the HCP.
  - People who have had SARS-CoV-2 infection in the last 90 days do not need to be tested if they remain asymptomatic, including those with a known contact.
- In health care facilities with an outbreak of SARS-CoV-2, recommendations for viral testing HCP, residents, and patients (regardless of vaccination status) remain unchanged.
- In nursing homes with an outbreak of SARS-CoV-2, HCP and residents, regardless of vaccination status, should have a viral test every 3-7 days until no new cases are identified for 14 days.
- Hospitals and dialysis facilities with an outbreak of SARS-CoV-2 should follow current recommendations for viral testing potentially exposed HCP and patients, regardless of vaccination status.
- The CDC has developed an online COVID-19 Viral Testing Tool that is an interactive web tool designed to help both health care providers and individuals understand COVID-19 testing options. This tool helps health care providers quickly access the most relevant, actionable information to determine what type(s) of COVID-19 testing they should recommend to patients. The tool helps individuals determine what type of test they should seek. After test results are in, the tool can help interpret test results and guide next steps. The version of this tool for providers is available at: [Guidance for Healthcare Workers about COVID-19 (SARS-CoV-2) Testing | CDC](https://www.cdc.gov/coronavirus/2019-ncov/lab/viral-testing-tool.html).

**Screening of Asymptomatic Populations at Higher Risk of Having or Transmitting SARS-CoV-2:**

Recent experience with outbreaks in nursing homes and those in need of urgent scheduled or unscheduled care, e.g. pregnant women, emergent surgery, has identified some frequently do not report typical symptoms such as fever, cough and shortness of breath; some may not report any symptoms. Unrecognized asymptomatic and pre-symptomatic infections likely contribute to transmission in these and other healthcare settings. Therefore, screening of those not listed in the priorities listed above are increasingly important and providers are requesting testing be made available.

CDC has recently updated their recommendations that apply to persons who are fully vaccinated against SARS-CoV-2, specifically that patient testing after exposure is not needed and screening tests prior to delivery of care is not necessary except for select operative procedures. (For colleagues who have been exposed, see the Exposure Assessment Tool.) The basis for this change is vaccine effectiveness (> 94%), and that even with breakthrough infection in those fully vaccinated, the viral load is very low and transmissibility is much less compared to those with natural infection who are not vaccinated. For colleagues, providers and clinicians the change in testing of those fully vaccinated does not change the need to wear appropriate PPE as defined in the PPE Guidebook.

See Table 1 for which populations should be tested, timing, and specific method of detection should be used. The assumptions supporting recommendations in Table 1 are:

- Rapid test methods provide shorter turn around time but often are less sensitive
- Rapid antigen test method is an acceptable method to test for infection for symptomatic patients. In some settings, e.g. skilled nursing facilities, rapid, point-of-care tests are also used for serial surveillance testing of those without symptoms.
- Adequate lab supplies and test kit capacity are available to meet priorities for Tier 1 or 2.
- As part of resuming operations, test all patients scheduled for a procedure that requires an overnight stay to allow for molecular test resulted prior to surgery performed within 2 midnights (two calendar days) prior to the procedure.

**NOTE:** Asymptomatic community members that wish to be tested should be referred to their primary care provider’s office, or to an available community testing provider. They should not be sent to the emergency room for testing. In addition to patient populations outlined in Table 1 the following are specific updates related to inpatients.
Test patients undergoing elective procedures/ surgeries expected to require overnight stay within 3 calendar days prior to date of the surgical procedure.

- If test capacity permits, expand testing to include: all hospitalized patients at the time of admission.
  - Molecular testing is recommended, but antigen testing is allowed if molecular testing resources are constrained.

**Admission & Pre-Procedure Testing Among Fully Vaccinated Persons:**

Operational considerations may impact a ministry’s testing approach and the following are examples of such considerations:

**Ministry Patient Care Unit Design -**
- a ministry with a large number of semi-private rooms may desire a more conservative testing approach that includes testing patients who are fully vaccinated compared to ministry that has all or mostly private rooms.
  - **Note:** Testing on admission protocol should remain for patients who are unvaccinated or if vaccine status cannot be verified to assure patients co-located in semi-occupancy rooms are negative for SARS-CoV-2.

**Incidence & Trends of Cases of SARS-CoV-2 Among the Population Served -**

Ministries should consider the prevalence of COVID-19 within their communities when determining the best approach to testing at the time of admission and pre-procedurally. Generally, ministries with a high number of cases within their community should continue admission and pre-procedure testing based on the recommendation below:

<table>
<thead>
<tr>
<th>Case Rates within the Community*</th>
<th>Testing Approach</th>
</tr>
</thead>
</table>
| Greater than 100/100K          | ● Test for all admissions  
                                   | ● Test outpatients when the provider determines the patient is at a higher risk for postoperative cardiac or pulmonary complications (see Table below), or other clinical basis |
| 50-99/100K                     | ● Test admissions who will be placed in a semi-occupancy room, for placement in a nonCOVID unit, patients who are not fully vaccinated, or have had a recent high-risk exposure, or the provider orders testing based on their clinical judgement.  
                                   | ● Test outpatients when the provider determines the patient is at a higher risk for postoperative cardiac or pulmonary complications, or other clinical basis |
| Less 50/100K                   | See exceptions for fully vaccinated persons directly below |

*Community case rates can be found on MercyOne COVID-19 Dashboard or the [CDC COVID Data Tracker](https://www.cdc.gov/coronavirus/2019-ncov/cases-statistics/data-tracker.html).
• All patients who are admitted for an overnight stay (observation, extended stay or inpatient) prior to an operative procedure should be tested for SARS-CoV-2 within 3 midnights (three calendar days) prior to the procedure with the following exceptions:

• **Exceptions for Fully vaccinated patients:**
  - Patients who are fully vaccinated AND have not reported a recent high-risk exposure, do not need routine pre-procedure testing or admission testing for SARS-CoV-2 (unless their provider orders testing based on their clinical judgement), even if they are expected to have an overnight stay.
  - Inpatients who are fully vaccinated do not need to be routinely tested prior to an operative procedure unless the patient’s provider determines the patient is at a higher risk for post-operative cardiac or pulmonary complications, or other clinical basis.
  - Patients who are fully vaccinated and scheduled for an outpatient procedure do not need to be tested preprocedure unless they have had a recent high-risk exposure.

• Patients who are undergoing an outpatient procedure who are NOT fully vaccinated (or whose status is unknown) who have reported a recent high-risk exposure, or who are at a higher risk for post-operative cardiac or pulmonary complications or for whom the provider has ordered testing based on clinical judgement should be tested for SARS-CoV-2 prior to the procedure should be tested within 3 midnights of the procedure.

**Examples of Underlying Conditions & Types of Operative Procedures for Which Risk of Postoperative Complications is High (include but are not limited to):**

<table>
<thead>
<tr>
<th>Underlying Conditions/ Co-Morbidities</th>
<th>Operative Procedure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes</td>
<td>Cardiac Surgery</td>
</tr>
<tr>
<td>Recovering from prior severe COVID19; refer to testing-algorithm-flu-reinfection.pdf for details on testing of these patients. Note: elective surgery for patients who’ve recovered should not be scheduled until at least 7 weeks after diagnosis unless the risks of deferring surgery outweigh the risk of postoperative morbidity or mortality associated with COVID-19.11</td>
<td>Thoracic Surgery</td>
</tr>
<tr>
<td>Chronic Lung Surgery</td>
<td>Vascular Surgery</td>
</tr>
<tr>
<td>Heart conditions (such as heart failure, coronary artery disease, cardiomyopathies or hypertension)</td>
<td>Neurosurgery</td>
</tr>
<tr>
<td>Need for emergency surgery</td>
<td></td>
</tr>
</tbody>
</table>

**NOTE:** Asymptomatic community members that wish to be tested should be referred to their primary care provider’s office, or to an available community testing provider. They should not be sent to the emergency room for testing. In addition to patient populations outlined in Table 1 the following are specific updates related to inpatients.
Table 1. Recommended Testing of Asymptomatic Patient Populations who are at higher risk of having and/or transmitting COVID-19 disease who present to the hospital for non-COVID-19 related services; Timing & Method.

<table>
<thead>
<tr>
<th>Patient Type</th>
<th>Vaccination Status</th>
<th>Timing</th>
<th>Rapid Testing</th>
<th>PCR Testing</th>
<th>Outside Lab</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pregnant woman</td>
<td>NOT fully vaccinated (or unknown)</td>
<td>upon arrival for delivery</td>
<td>x</td>
<td>Use only if Rapid Test Not Available</td>
<td></td>
</tr>
<tr>
<td></td>
<td>fully vaccinated</td>
<td>Testing test indicated</td>
<td>x</td>
<td>Use only if Rapid Test Available</td>
<td></td>
</tr>
<tr>
<td></td>
<td>fully vaccinated</td>
<td>Testing test indicated</td>
<td>x</td>
<td>Use only if Rapid Test Not Available</td>
<td></td>
</tr>
<tr>
<td>General Admissions</td>
<td>NOT fully vaccinated (or unknown)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>no procedures planned</td>
<td>full vaccinated</td>
<td>Testing test indicated</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Administered from Congregate Settings (e.g. Senior Residential Settings, Nursing Facilities, Assisted Living Facilities, Daycare Centers, Correctional or Detention Facilities)</td>
<td>NOT fully vaccinated (or unknown)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>full vaccinated</td>
<td>Testing test indicated</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surgical or invasive procedures</td>
<td>NOT fully vaccinated (or unknown)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overnight stay anticipated</td>
<td>full vaccinated</td>
<td>Testing test indicated</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surgical or invasive procedures</td>
<td>Regardless of vaccination status</td>
<td>Not only if at high risk for perioperative cardiac or pulmonary complications, reports of a recent high risk exposure, or as ordered by the provider</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Post-discharge to short-stay or assisted living</td>
<td>Regardless of vaccination status</td>
<td>Not only if at high risk for perioperative cardiac or pulmonary complications, reports of a recent high risk exposure, or as ordered by the provider</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Table reflects risks of SARS-CoV-2 testing.*

**Appendix:**

- Use only if Rapid Test Not Available
- Use only if Rapid Test Available
- Use only if results needed urgently, otherwise use standard PCR
- Use if rapid testing is recommended and not available in-house. Check with lab regarding turnaround time for results.
If expanded surveillance testing of asymptomatic Health Care Professionals is required, the CDC recommends the following:

- Fully vaccinated HCP may be exempt from expanded screening testing – refer to THSC System guide for updated requirements available from this link testing-resident-colleagues-congregate-settings.pdf
  - Vaccinated HCP still need to be tested:
    - if the HCP is symptomatic,
    - has a higher-risk exposure but is asymptomatic, or
    - is working in a facility experiencing an outbreak.
- In skilled nursing facilities, unvaccinated HCP must continue to participate in expanded screening testing - see THSC Guide.
- For other health care facilities or programs (e.g., PACE programs) that are performing expanded screening testing for asymptomatic HCP who do not have a known exposure, vaccinated HCP can be excluded from such a testing program. Refer to setting specific guidance for more details.

**Repeat Testing of Patients Who've Recovered from COVID-19**

There is ongoing investigation of the correlation between detection of SARS-CoV-2 RNA and period of transmissibility (infectivity) for a person with COVID-19; evidence to date indicates transmissibility is significantly reduced after acute infection. Therefore, repeat molecular testing after either 10 days following onset of symptoms or from date of initial detection of viral RNA is **NOT** recommended due to the likelihood that such testing only detects remnant RNA and it is unlikely that the person can transmit infection to others. For patients meeting either of the criteria below, repeat testing is **NOT** recommended.

- **Symptom-based Criteria for Patient with initial symptoms of acute SARS-CoV-2**
  - At least 1 day (24 hours) has passed since recovery defined as resolution of fever without the use of fever-reducing medications and improvement in respiratory symptoms (e.g., cough, shortness of breath); and,
  - At least 10 days have passed since symptoms first appeared
- **Time-based strategy for Patient with no symptoms of acute SARS-CoV-2 but tested positive**
  - 10 days have passed since the date of their first positive COVID-19 diagnostic test, assuming they have not subsequently developed symptoms since their positive test. Note, because symptoms cannot be used to gauge where these individuals are in the course of their illness, it is possible that the duration of viral shedding could be longer or shorter than 10 days after their first positive test.

Patients meeting these criteria do NOT need another molecular test prior to any subsequent outpatient procedure or inpatient surgery requiring an overnight inpatient admission. The patient should be treated as having recovered from the COVID viral infection.

**Antigen Testing**

Antigen tests are designed to detect proteins from the virus that causes COVID-19 in respiratory specimens, for example nasal swabs. Antigen tests are very specific for the virus but are not as sensitive as molecular tests. This means that a positive result is accurate, but a negative result does not rule out infection.

- Sensitivity = 60-80% (varies by brand of antigen assay), when compared to an EUA molecular test that uses nucleic acid amplification test (NAAT) method.
- Specificity = 98%-100%
Specimen can be either a nasopharyngeal (NP) and nasal (NS) swab tested either directly or after the swabs have been added to either Copan UTM or the CDC’s formulation of viral transport media (VTM)

Antigen is generally detectable in upper respiratory specimens during the acute phase of infection. See Table 1 for summary comparison of antigen to NAAT.

**Positive antigen result** - indicates that antigens from SARS-CoV-2 were detected, and the person tested is infected but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. If therapeutic or subsequent management actions are to be taken based on the positive result, providers should consider confirming the test result with a molecular test.

**Negative antigen result** - does not rule out COVID-19 and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19.

When evaluating the results of an antigen test for SARS-CoV-2 consider the performance characteristics (e.g., sensitivity, specificity) and the instructions for use of the FDA-authorized test, and the prevalence of SARS-CoV-2 infection in that particular community (percent positivity rate over the previous 7–10 days or the number of cases in the community relative to the population size).

Confirmatory testing of a positive antigen test, when indicated, should take place as soon as possible, e.g., not longer than 48 hours after the initial antigen testing.

- If more than 48 hours separate the two specimen collections, or if there have been opportunities for new exposures, a laboratory-based NAAT should be considered a separate test – not a confirmation of the earlier test. If the results are discordant between the antigen test and the confirmatory NAAT, in general the confirmatory test result should be interpreted as definitive for the purpose of clinical diagnosis.

**Examples of populations to screen using antigen tests:**
- Testing of residents, colleagues and clinicians in skilled nursing facilities under requirements from state-specific executive orders.
- Point of care / timely screening of persons scheduled for medically necessary outpatient procedures that require use of aerosol generating procedures (AGPs)
- Prior to initiation of immunosuppressive therapy
  - Rationale: Use of antigen test for screening conserves limited quantity of molecular test methods
- Community-focused testing

**Testing a symptomatic person in a community setting using Antigen Test:**
For more information see: CDC Antigen Testing Guidelines

At-home Testing
A health care provider might consider either an at-home collection kit or an at-home test if a patient has signs and symptoms of COVID-19 and cannot get tested by a health care provider. At-home collection kits and tests are available either by prescription or over the counter in a pharmacy or retail store without a prescription. Available at-home tests look for current infection. Since a prescription is not required for many of these tests, patients may choose to purchase and perform an at-home test without consulting a provider.

- Collection Kit – The specimen is collected in the home and then the specimen is sent for testing in an outside laboratory. These can be either PCR or antigen tests depending on the manufacturer.
- Collection Kit with At-home Test – The specimen is collected, and the test is performed in the home. These typically use either molecular or antigen test method.

The person must follow the manufacturer’s instructions exactly, and in the order specified for these tests to perform correctly. The FDA issues emergency use authorizations (EUA) for SARS-CoV-2 tests and it is important to verify an EUA has been issued by the FDA to the manufacturer of the in-home test kit. The EUA includes fact sheets that cover important information about the test kit and reminds patients and providers that all tests can experience false negative and false positive results. Individuals with positive results should self-isolate and seek additional care/direction from their health care provider. Individuals who test negative and experience COVID-19 like symptoms should follow up with their health care provider as negative results do not preclude an individual from SARS-CoV-2 infection.

Once a person engages the health care system (MGPS, ED, etc.) and reports a positive at-home test, the test result should be confirmed using a standard molecular or antigen (antigen, if capacity of molecular tests are limited) test ordered by the provider and run by the Clinical Laboratory to confirm the patient’s positive in-home test result. Prior to administering any EUA approved COVID-19 treatment, the diagnosis should be confirmed by lab testing that has FDA EUA. Providers may recommend treatment of a patient who reports positive at-home test who also has clinical symptoms.
of COVID-19 in addition to results of other laboratory or imaging tests while awaiting confirmation of the at-home test result.

If a colleague reports a positive COVID-19 at-home test, a standard, molecular or antigen (antigen, if capacity of molecular tests is limited) SARS-CoV-2 test should be performed to:

- Confirm the positive result
- Check for vaccination breakthrough in a vaccinated colleague (as applicable)

**Serological Antibody Test for SARS-CoV-2:**
Serological tests such as serum levels of IgM and IgG antibody against SARS-CoV-2 are important for understanding the epidemiology of emerging human coronaviruses (hCoVs), including the burden and role of asymptomatic infections to be clinically useful as the supplemental tests to the nucleic acid test.

The following is an important perspective and caution on interpretation and use of serologic testing from the IDSA.

As serological testing for SARS-CoV-2 advances, there are multiple issues that need to be addressed, from test quality to interpretation. Unlike molecular tests for COVID-19 (e.g., PCR), antibody tests may be better suited for public health surveillance and vaccine development than for diagnosis. The current antibody testing landscape is varied and clinically unverified, and these tests should not be used as the sole test for diagnostic decisions. Further, until more evidence about protective immunity is available,

- serology results should not be used to make staffing decisions or
decisions regarding the need for personal protective equipment.

**Guiding Principles for Providers when Considering Serologic Testing for SARS-CoV-2:**

✓ Person being tested understands their willingness to be tested is voluntary
✓ Providers ordering test are to provide consistent education to persons being tested on interpreting results – patient (test subject) education is being developed and will be on COVID-19 web
✓ Order testing that uses a platform (analyzer) that has demonstrated high specificity, ideally > 99%
✓ Goal for testing should be to improve colleague/patient health and safety and/or have operational implications
✓ Begin with testing groups/populations with medium or high prevalence of previous infection to minimize false positives
✓ Testing should be done that supports ongoing research, and understanding of value of serologic testing
✓ Testing can support identifying those who might donate convalescent plasma with understanding that agencies that collect plasma will repeat testing of potential donors with their method(s)

**Key Populations to Consider for Serologic Testing:**
- Patients and healthcare personnel (HCP), e.g. colleagues and clinicians who have recovered from confirmed COVID-19 infection.
- HCP without any symptoms of COVID-19 but have or are caring for PUIs or those with COVID-19 in units or areas with high volume of patients, e.g. cohort unit, Fever and Upper Respiratory Infection (FURI) clinics, and/or Emergency Department.
- Residents and colleagues in congregate living settings, especially skilled nursing and assisted living facilities, that have experienced outbreaks of COVID-19.

The clinical application of serologic testing is still evolving, and the System’s Clinical Lab leadership network is actively working on getting more experience with serologic diagnostics at a select number of RHMs. Serologic assays are more retrospective and timing of development of antibody typically is after initial detection of viral RNA using NAAT. (See Figure 1) There remain uncertainties like cross-reactivity of IgG antibodies with other endemic hCoVs, relationship of antibody to RT-PCR detection of viral RNA, sensitivity and specificity of serology in populations that may have high or low prevalence of infection, etc.

**Figure 2. Sequence of Detection of SARS-CoV-2 using Laboratory Diagnostics**

**Definitions**

**Fully Vaccinated:** A person is considered fully vaccinated if it has been 2 weeks after their second dose in a 2-dose series, such as the Pfizer or Moderna vaccines, or 2 weeks after a single-dose vaccine, such as Johnson & Johnson’s Janssen vaccine.
**High-Risk Exposure:** Prolonged contact (within 6 feet for a cumulative total of 15 minutes or more) with a person with COVID-19 who has symptoms (in the period from 2 days before symptom onset until they meet criteria for discontinuing home isolation; can be laboratory-confirmed or a clinically compatible illness), or a person who has tested positive for COVID-19 (laboratory confirmed) but has not had any symptoms (in the 2 days before the date of specimen collection until they meet criteria for discontinuing home isolation). This is irrespective of whether the person with COVID-19 or the contact was wearing a mask or whether the contact was wearing respiratory personal protective equipment (PPE).

**References:**


4. CDC. Interim Guidance for Antigen Testing for SARS-CoV-2 | CDC


Table 1. Summary of Some Differences between Nucleic Acid Amplification Tests (NAATs) and Antigen Tests
The decreased sensitivity of antigen tests might be offset if the point-of-care antigen tests are repeated more frequently (i.e. serial testing at least weekly).